Exabis Library
Welcome to the e-CCO Library!
P702: Off-label drug use in patients with inflammatory bowel disease: a national survey among tertiary care centres
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P703 Addition of azathioprine to switch of anti-TNF in patients with IBD in clinical relapse with pharacokinetic failure: A post hoc analysis of a prospective randomised trial using drug-tolerant assay
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P703: Clinical, radiographic and endoscopic remission with vedolizumab treatment in Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P703: Gut bacteria composition and familiality echo Inflammatory Bowel Disease type and pathological spectrum
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P703: Real world experience of the transition from the intravenous to subcutaneous formulation of vedolizumab in inflammatory bowel disease: A review of current data
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P703: Risk of disease progression in patients with Crohn's disease after 7 years of follow-up in a Danish population-based inception cohort
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P703: The real-world long-term effectiveness of vedolizumab in inflammatory bowel diseases: a single-centre observational study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P704 The biennial direct pharmaceutical costs per treatment with biologics for the inflammatory bowel disease in Greece: A comparative calculation study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P704: Association between trough levels of vedolizumab and therapy outcome in a cohort of patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P704: Bifidobacterium longum species protect murine colitis through different activation repertoires of immune cells
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P704: The effect of antiTNFα and anti-integrin agents on liver steatosis in inlamatory bowel disease patients with non-alcoholic fatty liver disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P704: The impact of travel distance on disease outcomes in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P704: Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P705 Dietary practices and beliefs of patients with older-onset inflammatory bowel disease: A prospective UK study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P705: Incidence and risk factors of micronutrient deficiency in the patients with inflammatory bowel disease in Korea: folate, vitamin B12, 25-OH-vitamin D, ferritin
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P705: Peripheral arterial disease is associated with an increased risk of elderly-onset inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P705: Switching from intravenous to subcutaneous infliximab: clinical and patient experience outcomes
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P705: Switching from originator to biosimilar infliximab—real-world data from 18 months prospective follow-up of a single-centre IBD population
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P705: The effects of commonly consumed dietary fibres on the gut microbiome and its fibre fermentative capacity in adults with inflammatory bowel disease in remission
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P706 Adalimumab drug levels at secondary loss of response in Crohn’s disease; are we aiming high enough? A retrospective, international multi-centre study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM